ACADEMIA

Tokyo Medical and Dental Univ. to Launch Investigator-Led Trial for JAK Inhibitor for CAEBV

January 10, 2019
Tokyo Medical and Dental University said on January 9 that its research group will commence an investigator-initiated clinical study of Novartis Pharma’s JAK1/2 inhibitor Jakavi (ruxolitinib) in patients with chronic active Epstein-Barr virus infection (CAEBV). CAEBV is a rare disease…

To read the full story

ACADEMIA

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…